Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AstraZeneca Drug Candidate Fails in Lung Cancer Study

By Stephanie Guzowski | August 9, 2016

Kirsty Wigglesworth/AP

The cancer field has experienced another setback this month.

AstraZeneca’s experimental drug selumetinib failed to meet its primary goal in a late-stage lung cancer trial. When the drug, an MEK 1/2 inhibitor, was combined with chemotherapy it did not slow lung cancer progression or prolong overall survival, the London-based drugmaker announced Tuesday.

The Phase 3 trial, SELECT-1, enrolled 510 patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who received either selumetinib or placebo in combination with chemotherapy. The trial followed promising Phase 2 results, which showed statistically-significant improvements in progression-free and overall survival.

Selumetinib is being studied as a treatment option in differentiated thyroid cancer and genetic disorder neurofibromatosis type 1. Last year, the drug failed in a trial for uveal melanoma, a rare disease in which cancer cells form in the eye’s tissue.

AstraZeneca has its focus on its recently launched cancer drugs Tagrisso and Lynparza. The company is also working on its cancer immunotherapy drug, durvalumab, particularly in hindsight of the challenge recently faced by Bristol-Myers Squibb’s Opdivo. Last Friday, BMS announced that Opdivo failed as a first-line treatment for advanced lung cancer in a clinical trial. Opdivo is approved to treat NSCLC after a patient has received chemotherapy. Still, the drug did not live up to major expectations that it would serve as a first-line therapy for patients.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE